Immutep Limited Stock Performance
| PRRUF Stock | USD 0.20 0.00 0.00% |
The company retains a Market Volatility (i.e., Beta) of 0.47, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Immutep's returns are expected to increase less than the market. However, during the bear market, the loss of holding Immutep is expected to be smaller as well. At this point, Immutep Limited has a negative expected return of -0.17%. Please make sure to check out Immutep's information ratio and rate of daily change , to decide if Immutep Limited performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Immutep Limited has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's basic indicators remain stable and the current disturbance on Wall Street may also be a sign of long-run gains for the company stockholders. ...more
| Begin Period Cash Flow | 88.1 M | |
| Total Cashflows From Investing Activities | -22.9 K |
Immutep |
Immutep Relative Risk vs. Return Landscape
If you would invest 23.00 in Immutep Limited on September 12, 2024 and sell it today you would lose (3.00) from holding Immutep Limited or give up 13.04% of portfolio value over 90 days. Immutep Limited is currently producing negative expected returns and takes up 3.0959% volatility of returns over 90 trading days. Put another way, 27% of traded pink sheets are less volatile than Immutep, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Immutep Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Immutep's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Immutep Limited, and traders can use it to determine the average amount a Immutep's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0545
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PRRUF |
Estimated Market Risk
| 3.1 actual daily | 27 73% of assets are more volatile |
Expected Return
| -0.17 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Immutep is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Immutep by adding Immutep to a well-diversified portfolio.
Immutep Fundamentals Growth
Immutep Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Immutep, and Immutep fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Immutep Pink Sheet performance.
| Return On Equity | -0.38 | |||
| Return On Asset | -0.23 | |||
| Operating Margin | (7.18) % | |||
| Current Valuation | 142.99 M | |||
| Shares Outstanding | 879.09 M | |||
| Price To Earning | (2.50) X | |||
| Price To Book | 2.81 X | |||
| Price To Sales | 33.12 X | |||
| Revenue | 247.66 K | |||
| EBITDA | (43.69 M) | |||
| Cash And Equivalents | 80 M | |||
| Cash Per Share | 0.09 X | |||
| Total Debt | 2.11 M | |||
| Debt To Equity | 0.02 % | |||
| Book Value Per Share | 0.11 X | |||
| Cash Flow From Operations | (30.23 M) | |||
| Earnings Per Share | (0.02) X | |||
| Total Asset | 148.52 M | |||
| Retained Earnings | (222 M) | |||
| Current Asset | 22 M | |||
| Current Liabilities | 1000 K | |||
About Immutep Performance
By analyzing Immutep's fundamental ratios, stakeholders can gain valuable insights into Immutep's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Immutep has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Immutep has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical products. Immutep Limited was incorporated in 1987 and is headquartered in Sydney, Australia. Immutep operates under Biotechnology classification in the United States and is traded on OTC Exchange.Things to note about Immutep Limited performance evaluation
Checking the ongoing alerts about Immutep for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Immutep Limited help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Immutep Limited generated a negative expected return over the last 90 days | |
| Immutep Limited has some characteristics of a very speculative penny stock | |
| Immutep Limited has high historical volatility and very poor performance | |
| The company reported the revenue of 247.66 K. Net Loss for the year was (32.21 M) with loss before overhead, payroll, taxes, and interest of (26.63 M). | |
| Immutep Limited has accumulated about 80 M in cash with (30.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.09. | |
| Latest headline from news.google.com: Long Term Trading Analysis for - Stock Traders Daily |
- Analyzing Immutep's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Immutep's stock is overvalued or undervalued compared to its peers.
- Examining Immutep's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Immutep's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Immutep's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Immutep's pink sheet. These opinions can provide insight into Immutep's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Immutep Pink Sheet analysis
When running Immutep's price analysis, check to measure Immutep's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immutep is operating at the current time. Most of Immutep's value examination focuses on studying past and present price action to predict the probability of Immutep's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immutep's price. Additionally, you may evaluate how the addition of Immutep to your portfolios can decrease your overall portfolio volatility.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |